- HK$36.60bn
- HK$21.56bn
- CNY17.70bn
Brief: 3Sbio Inc Says Clinical Trial Application Of Group's Drug Approved
Brief: 3SBIO Posts HY Net Profit Attributable RMB321.3 MLN
Brief: 3Sbio Says Clinical Trial Application Approved By National Medical Products Administration
Chinese pharma firm 3SBio at 4-week high ahead of product launch
Brief: 3Sbio Inc Posts FY Net Profit Attributable Of RMB1,277.2 Mln
China pharma firm 3SBIO jumps; co to expand oncology portfolio
Brief: 3Sbio's Unit Enters Collaboration Agreement With Samsung Bioepis
Brief: Samsung Biologics’ JV Samsung Bioepis Partners With Chinese Biopharma 3SBio
HK Exchange says 35 firms buy back shares
HK Exchange says 22 firms buy back shares
HK Exchange says 33 firms buy back shares
HK Exchange says 33 firms buy back shares
Brief: 3Sbio On Dec 19, Co Repurchased 3.4 Million Shares For Aggregate Purchase Price Of Hk$32.9 Million
Brief: 3Sbio Inc Posts HY Net Profit Attributable RMB514.2 Mln
3SBio leads slide in HK pharmaceutical firms amid China's vaccine scandal
Brief: 3SBio Says Unit To Provide Loan To Medical Recovery Of US$30 Mln
Brief: 3Sbio Inc Updates On Change In Price & Trading Volume Of Shares
Brief: 3SBio Inc Posts FY Net Profit Attributable RMB935.4 Mln
Brief: 3SBio Announces Tpiao Injection gets Approval For Clinical Trials For Additional Indication By CFDA